Navco Pharmaceuticals Inc. NAV.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 30.00K | 31.80K | 33.90K | 37.00K | 599.60K |
| Depreciation & Amortization | 0.00 | 0.00 | 500.00 | 1.00K | -27.80K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.00K | 31.80K | 34.40K | 38.00K | 571.80K |
| Operating Income | -30.00K | -31.80K | -34.40K | -38.00K | -571.80K |
| Income Before Tax | -50.00K | -53.20K | -53.70K | -57.00K | -670.90K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.05 | -0.05 | -0.05 | -0.06 | -0.67 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -50.00K | -53.20K | -53.70K | -57.00K | -670.90K |
| EBIT | -30.00K | -31.80K | -34.40K | -38.00K | -571.80K |
| EBITDA | -19.20K | -22.10K | -26.40K | -31.00K | -564.60K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | 228.28M | 228.28M | 228.28M | 228.28M | 228.31M |
| Average Diluted Shares Outstanding | 228.28M | 228.28M | 228.28M | 228.28M | 228.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |